Business · Markets · 2 hrs ago
Cochlear shares rise 9% in a week as analysts weigh recovery
Cochlear shares rose 9% in a week and were trading at $140.22 in early morning trade.
The Australian medical-device company makes hearing implants and its shares are listed on the ASX.
Despite the recent gain, the shares remain about 51% below their level a year ago.
Analysts mostly advise holding the shares, and their average price targets imply a small decline from the trading price.
Some analysts set a target as high as $165, suggesting the stock could move above $150 over the next 12 months.
Cochlear's latest results were mixed, but underlying net profit was ahead of forecasts and revenue was broadly in line.
Its FY27 profit guidance points to only modest growth, while the company's annual meeting next week may offer more information about its progress.
Cochlear shares rose 9% over the week to October 21, 2026, reaching $140.22 in early trading.
The shares were still about 51% below their level a year earlier, despite rising 56% from a 10-year low in late April.
Analyst ratings were mostly cautious, with average price targets below the trading price.
The Motley Fool AU article said Cochlear’s latest results suggested its business was getting back on track.
The article’s writer said the company’s annual general meeting the following week could provide more insight into its progress.
- Who
- Cochlear Ltd and analysts covering its shares.
- What
- Cochlear shares rose 9% in a week as analysts weighed the company’s recovery prospects.
- When
- October 21, 2026; the shares had risen over the previous week.
- Where
- Australia, on the ASX.
- Why
- The article said the latest result suggested the business was getting back on track, while analysts remained cautious about growth.
Analyst consensus
Motley Fool AU article's writer
Price outlook
Analyst consensus
Market Index data showed an average target of $131.37, implying about 6% downside. TradingView data showed an average target of $138.53, implying about 1% downside.
Motley Fool AU article's writer
The writer said the shares could climb past $150 in the coming months.
Business outlook
Analyst consensus
Morgans retained a hold rating, saying the FY27 earnings guidance implied only modest growth and no material earnings turnaround.
Motley Fool AU article's writer
The writer said the company’s long-term outlook remained intact and the year’s steep sell-offs were overdone.
Cochlear shares recorded a 10-year low.
The shares were up 9% over the previous week and traded at $140.22 in early morning trade.
Morgans retained a hold rating on the company.
Cochlear was due to hold its annual general meeting.
- Early trading price
- $140.22 per share
- Weekly share-price rise
- 9%
- Rise from 10-year low
- 56%
- Market Index average target
- $131.37 per share
- TradingView average target
- $138.53 per share
- FY27 NPAT guidance
- $330 million to $350 million
What people are saying
I still see Cochlear as a strong, globally dominant business with its long-term outlook intact.
I think the steep sell-offs this year were overdone.